Literature DB >> 30514508

Characterization of specific CD4 and CD8 T-cell responses in QuantiFERON TB Gold-Plus TB1 and TB2 tubes.

Nadia Pc Allen1, Gwendolyn Swarbrick2, Meghan Cansler2, Megan Null2, Hiam Salim3, Misato Miyamasu3, Jenny Howard3, Jeffrey Boyle3, David Lewinsohn2, Deborah Lewinsohn2.   

Abstract

The new generation of the IGRA QuantiFERON-TB Gold Plus (QFT-Plus) includes two antigen tubes, TB1 and TB2 which contain specific Mycobacterium tuberculosis peptides designed to stimulate both CD4 and CD8 T-cells. TB1 is designed to target cell mediated responses from CD4 T-cells, while TB2 contains newly designed peptides designed to also stimulate CD8 T-cells. We identified specific CD4 and CD8 T-cell clones that recognize different regions spanning the length of the CFP-10 protein in M. tuberculosisto directly test in QFT-Plus TB1 and TB2 tubes, followed by Interferon-gamma detection by the QFT-Plus ELISA. These clones showed specific responses to the different QFT-Plus tubes, the CD4 T-cell clone showed dose-dependent responses to both TB1 and TB2 tubes, while the CD8 T-cell clones showed specific and targeted responses to the QFT-Plus TB2 tube (>140-fold difference) versus the QFT-Plus TB1 tubes using the QFT-Plus ELISA. This testing provides direct evidence of the specificity of CD8 T-cell mediated response in QFT-Plus TB2 tubes.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  CD4 T-cell responses; CD8 T-cell responses; QFT-Plus; QuantiFERON; Tuberculosis (TB)

Mesh:

Substances:

Year:  2018        PMID: 30514508     DOI: 10.1016/j.tube.2018.10.014

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  5 in total

1.  End TB Strategy: Time to Move on From the Skin Test to the Interferon-γ Release Assays.

Authors:  Margaret Kruse; William Cruikshank
Journal:  Am J Public Health       Date:  2019-08       Impact factor: 9.308

2.  Comparing QuantiFERON-TB Gold Plus with Other Tests To Diagnose Mycobacterium tuberculosis Infection.

Authors:  Thara K Venkatappa; Rose Punnoose; Dolly J Katz; Michael P Higgins; Niaz Banaei; Edward A Graviss; Robert W Belknap; Christine S Ho
Journal:  J Clin Microbiol       Date:  2019-10-23       Impact factor: 5.948

3.  QuantiFERON-TB Gold Plus Assay in Patients With Latent vs. Active Tuberculosis in a Low Incidence Setting: Level of IFN-γ, CD4/CD8 Responses, and Release of IL-2, IP-10, and MIG.

Authors:  Séverine Carrère-Kremer; Pratt Kolia-Diafouka; Amandine Pisoni; Karine Bolloré; Marianne Peries; Sylvain Godreuil; Arnaud Bourdin; Philippe Van de Perre; Edouard Tuaillon
Journal:  Front Microbiol       Date:  2022-04-08       Impact factor: 5.640

4.  Prevalence of latent tuberculosis infection and feasibility of TB preventive therapy among Thai prisoners: a cross-sectional study.

Authors:  Sivaporn Gatechompol; Weerakit Harnpariphan; Ruamthip Supanan; Gompol Suwanpimolkul; Jiratchaya Sophonphan; Sasiwimol Ubolyam; Stephen J Kerr; Anchalee Avihingsanon; Kamon Kawkitinarong
Journal:  BMC Public Health       Date:  2021-06-24       Impact factor: 3.295

5.  Retrospective Performance Analyses of over Two Million U.S. QuantiFERON Blood Sample Results.

Authors:  Caixia Bi; Richard B Clark; Ronald Master; Hema Kapoor; Martin H Kroll; Ann E Salm; William A Meyer
Journal:  Microbiol Spectr       Date:  2021-07-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.